Seikagaku Corporation

Tokyo Stock Exchange 4548.T

Seikagaku Corporation Capital Expenditure for the year ending March 31, 2024: USD -30.13 M

Seikagaku Corporation Capital Expenditure is USD -30.13 M for the year ending March 31, 2024, a -95.06% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • Seikagaku Corporation Capital Expenditure for the year ending March 31, 2023 was USD -15.45 M, a 8.29% change year over year.
  • Seikagaku Corporation Capital Expenditure for the year ending March 31, 2022 was USD -16.84 M, a 9.34% change year over year.
  • Seikagaku Corporation Capital Expenditure for the year ending March 31, 2021 was USD -18.57 M, a -1.19% change year over year.
  • Seikagaku Corporation Capital Expenditure for the year ending March 31, 2020 was USD -18.36 M, a -67.51% change year over year.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
Loading...
SV Wall Street
Tokyo Stock Exchange: 4548.T

Seikagaku Corporation

CEO Mr. Kenji Mizutani
IPO Date March 23, 2004
Location Japan
Headquarters Marunouchi Center Building
Employees 988
Sector Healthcare
Industries
Description

Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates in two segments, Pharmaceuticals and LAL. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN, OPEGAN Hi, and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and cross-linked hyaluronate hydrogel for knee osteoarthritis under the brand name Gel-One, as well as HERNICORE for the treatment of lumbar disc herniation. The company also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, it develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals, biological products, medical devices, manufacturing processes, and water quality control of dialysate under the brands, such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for osteoarthritis; SI-613-ETP to treat enthesopathy; and SI-449, a powdered adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.

Similar companies

4521.T

Kaken Pharmaceutical Co., Ltd.

USD 28.07

-2.08%

4549.T

Eiken Chemical Co., Ltd.

USD 14.13

-0.05%

4506.T

Sumitomo Pharma Co., Ltd.

USD 5.05

1.23%

4042.T

Tosoh Corporation

USD 13.75

-2.23%

4552.T

JCR Pharmaceuticals Co., Ltd.

USD 3.51

6.45%

StockViz Staff

February 8, 2025

Any question? Send us an email